<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591652</url>
  </required_header>
  <id_info>
    <org_study_id>2020KT81</org_study_id>
    <nct_id>NCT04591652</nct_id>
  </id_info>
  <brief_title>99mTc-MIRC208 SPECT/CT Imaging for HER2-Positive Cancer Patients</brief_title>
  <official_title>A Novel VHH-Based Radiotracer, 99mTc-MIRC208, for SPECT/CT Imaging of HER2-Positive Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-labeled Single-Photon Emission Computed Tomography/Computed&#xD;
      Tomography(SPECT/CT) study to investigate the clinical value of 99mTc-MIRC208 in HER2 status&#xD;
      measurement of cancer patients. A single dose of 14.8 MBq/kg body weight will be injected&#xD;
      intravenously. The whole-body SPECT/CT examination will be performed 2 h post-injection and&#xD;
      the visual and semiquantitative methods will be used to assess the SPECT/CT images.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HER2 is an important therapeutic target for cancer. Immunohistochemistry(IHC) and&#xD;
      fluorescence in situ hybridization (FISH) are two standard approaches for HER2 status&#xD;
      determination and selection of patients who will undergo the anti-HER2 therapy. However, the&#xD;
      intra- and intratumor heterogeneity over space and time make them even more challenging to&#xD;
      assess HER2 status. HER2-specific nuclear molecular imaging is a potential tool, which has&#xD;
      ability to detect HER2 receptor in primary and metastatic lesions noninvasively and address&#xD;
      the problems encountered by biopsy dependent tests. VHH, also referred to as nanobody, is a&#xD;
      distinct type of antibody fragment derived from camelid heavy chain-only antibody. Compared&#xD;
      with classical antibodies, VHHs have smaller size (about 15 kDa), greater thermal and&#xD;
      chemical stability, which promoting their application in field of cancer theranostic.&#xD;
&#xD;
      In our recent preclinical studies, we developed a novel VHH-based radiotracer, 99mTc-MIRC208,&#xD;
      for the SPECT/CT imaging of HER2 status in tumors. In this clinical study, we aim to&#xD;
      investigate whether 99mTc-MIRC208 could be used for HER2 measurement in cancer patients.&#xD;
      99mTc-MIRC208 SPECT/CT examination will be performed in patients with HER2-positive tumors.&#xD;
      The SUV of 99mTc-MIRC208 in tumors will be calculated. Meanwhile, we will investigate the&#xD;
      ability of 99mTc-MIRC208 for the patients selection for anti-HER2 therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUV</measure>
    <time_frame>3 years</time_frame>
    <description>The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value (SUV) on PET/CT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>99mTc-MIRC208 SPECT/CT scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The cancer patients will be injected with14.8 MBq/kg body weight, and 2h later, SPECT/CT scan will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99mTc-MIRC208</intervention_name>
    <description>99mTc-MIRC208 SPECT/CT: after intravenous injection of 14.8 MBq/kg body weight of quality-controlled 99mTc-MIRC208 2 h, a Siemens Symbia T16 SPECT/CT scan will be performed within 1 h.</description>
    <arm_group_label>99mTc-MIRC208 SPECT/CT scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged # 18 years old; ECOG 0 or 1;&#xD;
&#xD;
          2. Patients with HER2 positive or suspicious positive tumors;&#xD;
&#xD;
          3. Has at least one measurable target lesion according to CT or MRI;&#xD;
&#xD;
          4. Life expectancy â‰¥ 12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant hepatic or renal dysfunction;&#xD;
&#xD;
          2. Is pregnant or ready to pregnant;&#xD;
&#xD;
          3. Cannot keep their states for half an hour;&#xD;
&#xD;
          4. Refused to join the clinical research;&#xD;
&#xD;
          5. Suffering from claustrophobia or other mental disorders;&#xD;
&#xD;
          6. Any other situation that researchers considered it unsuitable to participate in the&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hua Zhu</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunlian Zhou</last_name>
      <phone>010-88196391</phone>
      <email>zhoushunlian@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>VHH</keyword>
  <keyword>SPECT/CT</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

